Document Type
Conference Proceeding
Publication Date
5-11-2025
Abstract
Pembrolizumab was granted accelerated FDA approval for the treatment of patients with metastatic MMR deficient solid tumors and has shown significant benefit in the treatment of metastatic colorectal cancer. Recently, the NICHE-2 trial demonstrated that neoadjuvant nivolumab plus ipilimumab led to a significant response in locally advanced MMR deficient colon cancer. This report is a single institution's experience regarding the treatment of metastatic colon cancer with neoadjuvant immunotherapy. Since 2022, our institution has treated two patients with neoadjuvant pembrolizumab for metastatic colon cancer and achieved complete clinical and pathologic responses with no residual evidence of malignancy.
Recommended Citation
Applegarth J, Hao SB, Bova C, Wasvary H. Metastatic colon cancer and single agent neoadjuvant immunotherapy: a single institution experience. Paper presented at: ASCRS 2025 Annual Scientific Meeting; 2025 May 10-13; San Diego, CA.
Comments
ASCRS 2025 Annual Scientific Meeting, San Diego, California, May 10-13, 2025.